Lee Howard D, Yuan Li-Yun
Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States..
Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States.
World J Hepatol. 2024 May 27;16(5):684-687. doi: 10.4254/wjh.v16.i5.684.
In this editorial we comment on the review by Zhou reviewing the landscape of nanomedicine in the treatment of hepatocellular carcinoma (HCC). We focus on the immense potential of nanotechnology, particularly ligand-receptor mediated nanotherapy, in revolutionizing the treatment landscape of HCC. Despite advancements in multidisciplinary treatment, HCC remains a significant global health challenge. Ligand-mediated nanotherapy offers the opportunity for precise drug delivery to tumor sites, targeting specific receptors overexpressed in HCC cells, thereby enhancing efficacy and minimizing side effects. Overcoming drug resistance and aggressive tumor biology is facilitated by nanomedicine, bypassing traditional hurdles encountered in chemotherapy. Examples include targeting glypican-3, asialoglycoprotein, transferrin receptor or folic acid receptors, capitalizing on their over-expression in tumor cells. The ability for multi-receptor targeting through dual-ligand nanoparticle modification holds the prospect of further enhancement in specificity and efficacy of directed therapy. However, challenges including immune responses, reproducibility in nanoparticle synthesis, and production scalability remain. Future directions involve refining targeting strategies, improving drug release mechanisms, and streamlining production processes to enable personalized and multifunctional nanotherapies. Overall, the integration of nanotherapy in HCC treatment holds immense promise, but continued partnership and effort are needed in offering hope for more effective, precise, and accessible clinical care in the management of HCC.
在这篇社论中，我们对周的综述进行评论，该综述探讨了纳米医学在肝细胞癌（HCC）治疗中的现状。我们聚焦于纳米技术的巨大潜力，尤其是配体-受体介导的纳米疗法，它正在彻底改变HCC的治疗格局。尽管多学科治疗取得了进展，但HCC仍然是一项重大的全球健康挑战。配体介导的纳米疗法为将药物精准递送至肿瘤部位提供了机会，靶向HCC细胞中过度表达的特定受体，从而提高疗效并将副作用降至最低。纳米医学有助于克服耐药性和侵袭性肿瘤生物学特性，绕过化疗中遇到的传统障碍。例如，靶向磷脂酰肌醇蛋白聚糖-3、去唾液酸糖蛋白、转铁蛋白受体或叶酸受体，利用它们在肿瘤细胞中的过度表达。通过双配体纳米颗粒修饰实现多受体靶向的能力有望进一步提高定向治疗的特异性和疗效。然而，包括免疫反应、纳米颗粒合成的可重复性以及生产规模扩大等挑战依然存在。未来的方向包括完善靶向策略、改进药物释放机制以及简化生产流程，以实现个性化和多功能纳米疗法。总体而言，纳米疗法在HCC治疗中的整合具有巨大潜力，但需要持续的合作与努力，为HCC管理中更有效、精准和可及的临床护理带来希望。
